{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:40:59Z","timestamp":1793047259466,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pharming Group N.V"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12325-025-03252-1","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T03:46:55Z","timestamp":1750477615000},"page":"4048-4066","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Impact of Activated Phosphoinositide 3-Kinase\u00a0\u03b4 Syndrome (APDS) on Health-Related Quality of Life (HRQoL): Elicitation of Health State Utility Values Through Time Trade-Off (TTO) and EQ-5D"],"prefix":"10.1007","volume":"42","author":[{"given":"Joanne B.","family":"Tutein Nolthenius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Wyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Enstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"issue":"2","key":"3252_CR1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","volume":"139","author":"TI Coulter","year":"2017","unstructured":"Coulter TI, Chandra A, Bacon CM, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase\u00a0\u03b4 syndrome: a large patient cohort study. J Allergy Clin Immunol. 2017;139(2):597\u2013606.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3252_CR2","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaci.2018.04.032","volume":"143","author":"T Okano","year":"2019","unstructured":"Okano T, Imai K, Tsujita Y, et al. Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase\u00a0\u03b4 syndrome type\u00a01. J Allergy Clin Immunol. 2019;143(1):266\u201375.","journal-title":"J Allergy Clin Immunol"},{"key":"3252_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3389\/fimmu.2018.00338","volume":"9","author":"AM Condliffe","year":"2018","unstructured":"Condliffe AM, Chandra A. Respiratory manifestations of the activated phosphoinositide 3-kinase delta syndrome. Front Immunol. 2018;9:338.","journal-title":"Front Immunol"},{"issue":"6","key":"3252_CR4","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3349\/ymj.2020.61.6.542","volume":"61","author":"J-M Kang","year":"2020","unstructured":"Kang J-M, Kim SK, Kim D, et al. Successful sirolimus treatment for korean patients with activated phosphoinositide 3-kinase\u00a0\u03b4 syndrome 1: the first case series in Korea. Yonsei Med J. 2020;61(6):542.","journal-title":"Yonsei Med J"},{"key":"3252_CR5","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3389\/fimmu.2018.02043","volume":"9","author":"TI Coulter","year":"2018","unstructured":"Coulter TI, Cant AJ. The treatment of activated PI3K\u03b4 syndrome. Front Immunol. 2018;9:2043.","journal-title":"Front Immunol"},{"issue":"1","key":"3252_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13223-020-00420-6","volume":"16","author":"M Ewertowska","year":"2020","unstructured":"Ewertowska M, Grze\u015bk E, Urba\u0144czyk A, et al. Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS 1 and APDS 2): similarities and differences based on clinical presentation in two boys. Allergy Asthma Clin Immunol. 2020;16(1):1\u20137.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"13","key":"3252_CR7","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1084\/jem.20141759","volume":"211","author":"CL Lucas","year":"2014","unstructured":"Lucas CL, Zhang Y, Venida A, et al. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J Exp Med. 2014;211(13):2537\u201347.","journal-title":"J Exp Med"},{"key":"3252_CR8","doi-asserted-by":"publisher","first-page":"1208567","DOI":"10.3389\/fimmu.2023.1208567","volume":"14","author":"S Vanselow","year":"2023","unstructured":"Vanselow S, Wahn V, Schuetz C. Activated PI3K\u03b4 syndrome\u2013reviewing challenges in diagnosis and treatment. Front Immunol. 2023;14:1208567.","journal-title":"Front Immunol"},{"issue":"1","key":"3252_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ni.2771","volume":"15","author":"CL Lucas","year":"2014","unstructured":"Lucas CL, Kuehn HS, Zhao F, et al. Dominant-activating, germline mutations in phosphoinositide 3-kinase p110\u03b4 cause T\u00a0cell senescence and human immunodeficiency. Nat Immunol. 2014;15(1):88.","journal-title":"Nat Immunol"},{"key":"3252_CR10","unstructured":"Pharming Group N.V. Pharming announces positive data from phase\u00a0II\/III leniolisib trial presented at Clinical Immunology Society 2022 Annual Meeting 2022. Updated 01 April. https:\/\/www.prnewswire.com\/in\/news-releases\/pharming-announces-positive-data-from-phase-ii-iii-leniolisib-trial-presented-at-clinical-immunology-society-2022-annual-meeting-899610831.html. Accessed 24 Sept 2024."},{"issue":"1","key":"3252_CR11","doi-asserted-by":"publisher","first-page":"210.e9","DOI":"10.1016\/j.jaci.2016.03.022","volume":"138","author":"E Elkaim","year":"2016","unstructured":"Elkaim E, Neven B, Bruneau J, et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase\u00a0\u03b4 syndrome 2: a cohort study. J Allergy Clin Immunol. 2016;138(1):210\u20138.e9.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"3252_CR12","doi-asserted-by":"publisher","first-page":"984.e10","DOI":"10.1016\/j.jaci.2023.06.015","volume":"152","author":"ME Maccari","year":"2023","unstructured":"Maccari ME, Wolkewitz M, Schwab C, et al. Activated phosphoinositide 3-kinase\u00a0\u03b4 syndrome: update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity. J Allergy Clin Immunol. 2023;152(4):984\u201396.e10.","journal-title":"J Allergy Clin Immunol"},{"key":"3252_CR13","unstructured":"Pharming Data on File. Systematic literature review to identify epidemiological, clinical and economic evidence in APDS. 2023."},{"issue":"6","key":"3252_CR14","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2020.12.017","volume":"24","author":"LS Matza","year":"2021","unstructured":"Matza LS, Stewart KD, Lloyd AJ, Rowen D, Brazier JE. Vignette-based utilities: usefulness, limitations, and methodological recommendations. Value Health. 2021;24(6):812\u201321.","journal-title":"Value Health"},{"key":"3252_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10198-019-01136-0","volume":"21","author":"LS Matza","year":"2020","unstructured":"Matza LS, Paramore LC, Stewart KD, Karn H, Jobanputra M, Dietz AC. Health state utilities associated with treatment for transfusion-dependent \u03b2-thalassemia. Eur J Health Econ. 2020;21:397\u2013407.","journal-title":"Eur J Health Econ"},{"issue":"9","key":"3252_CR16","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1080\/13696998.2020.1776719","volume":"23","author":"LS Matza","year":"2020","unstructured":"Matza LS, Phillips GA, Howell TA, Ciffone N, Ahmad Z. Estimating health state utilities associated with a rare disease: familial chylomicronemia syndrome (FCS). J Med Econ. 2020;23(9):978\u201384.","journal-title":"J Med Econ"},{"issue":"3","key":"3252_CR17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/bjd.14647","volume":"175","author":"F Rencz","year":"2016","unstructured":"Rencz F, Brodszky V, Stalmeier P, et al. Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment. Br J Dermatol. 2016;175(3):593\u20139.","journal-title":"Br J Dermatol"},{"issue":"11","key":"3252_CR18","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1136\/bjophthalmol-2018-313089","volume":"103","author":"A Lloyd","year":"2019","unstructured":"Lloyd A, Piglowska N, Ciulla T, et al. Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy. Br J Ophthalmol. 2019;103(11):1610\u20134.","journal-title":"Br J Ophthalmol"},{"key":"3252_CR19","unstructured":"Rowen D, Brazier J, Wong R, Wailoo A. Measuring and valuing health-related quality of life when sufficient EQ-5D data is not available University of Sheffield 2020. https:\/\/www.sheffield.ac.uk\/nice-dsu\/methods-development\/measuring-health-related-quality-life. Accessed 12 April 2024."},{"key":"3252_CR20","unstructured":"NICE. NICE health technology evaluations: the manual 2022. Updated 31st January. https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741. Accessed 24 Sept 2024."},{"key":"3252_CR21","unstructured":"Pharming Data on File. Leniolisib expert perspective and insight consultancy to inform UK Health Technology Assessment Report (In Development). 2023."},{"key":"3252_CR22","unstructured":"NICE. Position statement on use of the EQ-5D-5L value set for England 2019. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/technology-appraisal-guidance\/eq-5d-5l. Accessed 24 Sept 2024."},{"key":"3252_CR23","unstructured":"Tolley K. What are health utilities? 2009. http:\/\/www.bandolier.org.uk\/painres\/download\/What%20is%202009\/What_are_health_util.pdf. Accessed 24 Sept 2024."},{"key":"3252_CR24","doi-asserted-by":"crossref","unstructured":"Maccari ME, Abolhassani H, Aghamohammadi A, et al. Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase\u00a0\u03b4 syndrome: the European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase\u00a0\u03b4 Syndrome Registry. Front Immunol. 2018;9:543.","DOI":"10.3389\/fimmu.2018.00543"},{"issue":"5","key":"3252_CR25","doi-asserted-by":"publisher","first-page":"1332.e5","DOI":"10.1016\/j.jaci.2021.04.015","volume":"148","author":"J Thalhammer","year":"2021","unstructured":"Thalhammer J, Kindle G, Nieters A, et al. Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations. J Allergy Clin Immunol. 2021;148(5):1332\u201341.e5.","journal-title":"J Allergy Clin Immunol"},{"key":"3252_CR26","volume-title":"NICE DSU technical support document 11: alternatives to EQ-5D for generating health state utility values","author":"J Brazier","year":"2011","unstructured":"Brazier J, Rowen D. NICE DSU technical support document 11: alternatives to EQ-5D for generating health state utility values. London: NICE Decision Support Unit Technical Support Documents; 2011."},{"key":"3252_CR27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fimmu.2018.00543","volume":"9","author":"M Maccari","year":"2018","unstructured":"Maccari M, Abolhassani H, Aghamohammadi A, et al. Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase\u00a0\u03b4 syndrome: the European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase\u00a0\u03b4 syndrome registry. Front Immunol. 2018;9:543.","journal-title":"Front Immunol"},{"key":"3252_CR28","unstructured":"Pharming Data on File. Prevalence of APDS manfiestations. 2024."},{"issue":"1","key":"3252_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hec.3564","volume":"27","author":"NJ Devlin","year":"2018","unstructured":"Devlin NJ, Shah KK, Feng Y, Mulhern B, Van Hout B. Valuing health-related quality of life: an EQ-5D-5 L value set for England. Health Econ. 2018;27(1):7\u201322.","journal-title":"Health Econ"},{"key":"3252_CR30","unstructured":"EuroQol. New UK EQ-5D-5L valuation study blog 2023. Updated 7 December 2023. https:\/\/euroqol.org\/about-us\/blogs\/. Accessed 12 April 2024."},{"key":"3252_CR31","unstructured":"NICE. Position statement on use of the EQ-5D-5L value set for England (updated October 2019) 2019. Updated October 2019. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/technology-appraisal-guidance\/eq-5d-5l. Accessed 12 April 2024."},{"issue":"2","key":"3252_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40273-022-01218-7","volume":"41","author":"M Hern\u00e1ndez Alava","year":"2023","unstructured":"Hern\u00e1ndez Alava M, Pudney S, Wailoo A. Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK population study. Pharmacoeconomics. 2023;41(2):199\u2013207.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"3252_CR33","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40273-016-0404-1","volume":"34","author":"M Oppe","year":"2016","unstructured":"Oppe M, Rand-Hendriksen K, Shah K, Ramos-Goni JM, Luo N. EuroQol protocols for time trade-off valuation of health outcomes. Pharmacoeconomics. 2016;34(10):993\u20131004.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"3252_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13023-024-03215-9","volume":"19","author":"I Hitchcock","year":"2024","unstructured":"Hitchcock I, Skrobanski H, Matter E, et al. A qualitative study to explore the burden of disease in activated phosphoinositide 3-kinase delta syndrome (APDS). Orphanet J Rare Dis. 2024;19(1):203.","journal-title":"Orphanet J Rare Dis"},{"key":"3252_CR35","unstructured":"NICE. Asfotase alfa for treating paediatric-onset hypophosphatasia 2023. Updated 1 March 2023. https:\/\/www.nice.org.uk\/guidance\/hst23\/resources\/asfotase-alfa-for-treating-paediatriconset-hypophosphatasia-pdf-50216317635013. Accessed 9 July 2024."},{"key":"3252_CR36","unstructured":"NICE. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type\u00a02 2019. Updated 27 November 2019. https:\/\/www.nice.org.uk\/guidance\/hst12\/resources\/cerliponase-alfa-for-treating-neuronal-ceroid-lipofuscinosis-type-2-pdf-50216255489221. Accessed 9 July 2024."},{"key":"3252_CR37","unstructured":"NICE. Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations 2019. https:\/\/www.nice.org.uk\/guidance\/hst11\/resources\/voretigene-neparvovec-for-treating-inherited-retinal-dystrophies-caused-by-rpe65-gene-mutations-pdf-50216253809605. Accessed 9 July 2024."},{"key":"3252_CR38","doi-asserted-by":"crossref","unstructured":"Lo SH, Lloyd A, Elkhalifa S, Sisic Z, van Nooten FE. Time trade-off utilities for hereditary angioedema health and caregiver states. PharmacoEconomics-Open. 2022:6(2):231\u20139.","DOI":"10.1007\/s41669-021-00302-6"},{"key":"3252_CR39","doi-asserted-by":"crossref","unstructured":"Andayani TM, Kristina SA, Endarti D, Wahyuni ST, Rahmawati A. Health utility score in type\u00a02 diabetes mellitus. Pharm Sci Asia. 2020;47(3):246\u201352.","DOI":"10.29090\/psa.2020.03.019.0040"},{"issue":"2","key":"3252_CR40","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jval.2022.07.005","volume":"26","author":"S McNamara","year":"2023","unstructured":"McNamara S, Schneider PP, Love-Koh J, Doran T, Gutacker N. Quality-adjusted life expectancy norms for the English population. Value Health. 2023;26(2):163\u20139.","journal-title":"Value Health"},{"key":"3252_CR41","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13023-025-03734-z","volume":"20","author":"M Mahendran","year":"2025","unstructured":"Mahendran M, Upton JE, Ramasubramanian R, et al. Overall survival among patients with activated phosphoinositide 3-kinase delta syndrome (APDS). Orphanet J Rare Dis. 2025;20:212.","journal-title":"Orphanet J Rare Dis"},{"key":"3252_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12016-019-08738-9","volume":"59","author":"M Jamee","year":"2020","unstructured":"Jamee M, Moniri S, Zaki-Dizaji M, et al. Clinical, immunological, and genetic features in patients with activated PI3K\u03b4 syndrome (APDS): a systematic review. Clin Rev Allergy Immunol. 2020;59:323\u201333.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"3252_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004154","volume":"20","author":"EW Butterly","year":"2023","unstructured":"Butterly EW, Hanlon P, Shah AS, et al. Comorbidity and health-related quality of life in people with a chronic medical condition in randomised clinical trials: an individual participant data meta-analysis. PLoS Med. 2023;20(1):e1004154.","journal-title":"PLoS Med"},{"key":"3252_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2019.04.005","volume":"53","author":"TT Makovski","year":"2019","unstructured":"Makovski TT, Schmitz S, Zeegers MP, Stranges S, van den Akker M. Multimorbidity and quality of life: systematic literature review and meta-analysis. Ageing Res Rev. 2019;53:100903.","journal-title":"Ageing Res Rev"},{"key":"3252_CR45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11136-015-1061-0","volume":"25","author":"MC Adriaanse","year":"2016","unstructured":"Adriaanse MC, Drewes HW, Van Der Heide I, Struijs JN, Baan CA. The impact of comorbid chronic conditions on quality of life in type\u00a02 diabetes patients. Qual Life Res. 2016;25:175\u201382.","journal-title":"Qual Life Res"},{"key":"3252_CR46","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3389\/fneur.2020.00851","volume":"11","author":"M Magyari","year":"2020","unstructured":"Magyari M, Sorensen PS. Comorbidity in multiple sclerosis. Front Neurol. 2020;11:851.","journal-title":"Front Neurol"},{"issue":"5","key":"3252_CR47","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/ajt.14081","volume":"17","author":"JP Singer","year":"2017","unstructured":"Singer JP, Katz PP, Soong A, et al. Effect of lung transplantation on health-related quality of life in the era of the lung allocation score: a US prospective cohort study. Am J Transplant. 2017;17(5):1334\u201345.","journal-title":"Am J Transplant"},{"key":"3252_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-016-0465-z","volume":"14","author":"CT Solem","year":"2016","unstructured":"Solem CT, Vera-Llonch M, Liu S, Botteman M, Castiglione B. Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis. Health Qual Life Outcomes. 2016;14:1\u20139.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"3252_CR49","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/irv.12506","volume":"12","author":"EB Fragaszy","year":"2018","unstructured":"Fragaszy EB, Warren-Gash C, White PJ, et al. Effects of seasonal and pandemic influenza on health-related quality of life, work and school absence in England: results from the Flu Watch cohort study. Influenza Other Respir Viruses. 2018;12(1):171\u201382.","journal-title":"Influenza Other Respir Viruses"},{"key":"3252_CR50","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2165\/00019053-200220070-00003","volume":"20","author":"RL Akehurst","year":"2002","unstructured":"Akehurst RL, Brazier JE, Mathers N, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics. 2002;20:455\u201362.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"3252_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-018-0897-8","volume":"16","author":"N Castej\u00f3n","year":"2018","unstructured":"Castej\u00f3n N, Cappelleri JC, Cuervo J, et al. Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom. Health Qual Life Outcomes. 2018;16(1):1\u20139.","journal-title":"Health Qual Life Outcomes"},{"key":"3252_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12963-018-0170-8","volume":"16","author":"M Mart\u00ed-Pastor","year":"2018","unstructured":"Mart\u00ed-Pastor M, Pont A, \u00c1vila M, et al. Head-to-head comparison between the EQ-5D-5L and the EQ-5D-3L in general population health surveys. Popul Health Metrics. 2018;16:1\u201311.","journal-title":"Popul Health Metrics"},{"issue":"1","key":"3252_CR53","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12955-023-02188-w","volume":"21","author":"CP Klapproth","year":"2023","unstructured":"Klapproth CP, Fischer F, Rose M. Scale agreement, ceiling and floor effects, construct validity, and relative efficiency of the PROPr and EQ-5D-3L in low back pain patients. Health Qual Life Outcomes. 2023;21(1):107.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"3252_CR54","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/01.mlr.0000160419.27642.a8","volume":"43","author":"AS Pickard","year":"2005","unstructured":"Pickard AS, Knight SJ. Proxy evaluation of health-related quality of life: a conceptual framework for understanding multiple proxy perspectives. Med Care. 2005;43(5):493.","journal-title":"Med Care"},{"issue":"11","key":"3252_CR55","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/hec.1006","volume":"14","author":"S Petrou","year":"2005","unstructured":"Petrou S, Hockley C. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population. Health Econ. 2005;14(11):1169\u201389.","journal-title":"Health Econ"},{"issue":"1","key":"3252_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-021-01829-x","volume":"16","author":"P Gissen","year":"2021","unstructured":"Gissen P, Specchio N, Olaye A, et al. Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type\u00a02). Orphanet J Rare Dis. 2021;16(1):1\u201313.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03252-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03252-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03252-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T21:20:33Z","timestamp":1757193633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03252-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3252"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03252-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"At the time of this research, Joanne Tutein Nolthenius and John Whalen were employed by Pharming Group N.V. Annabel Griffiths was employed by Costello Medical and was embedded within Pharming Group N.V. when this work was research was complete. Research execution was delivered by Olivia Dodd, Robin Wyn, and Ashley Enstone who were employed by Adelphi Values PROVE\u2122 at the time this research was commissioned by Pharming Group N.V.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethics exemption for this non-interventional study was sought from Salus IRB and was granted on 1\u00a0December 2022 (study ID: #22256\u201301), as per Code of Federal Regulations 46.104(d)(2(i)) addressing research comprising only educational tests, surveys, interviews and\/or observation, where participants remain anonymous. All study participants provided informed consent prior to their involvement.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}